b*****h
发帖数: 783 | 1 need about more 4 weeks. |
f**********g
发帖数: 2252 | 2 MannKind Says FDA Review Of Afrezza To Take Four More Weeks
0 minutes ago - Dow Jones News
Related Companies
Symbol Last %Chg
MNKD 7.97 0.00%
As of 4:00 PM ET 12/27/10
DOW JONES NEWSWIRES
MannKind Corp. (MNKD) said the U.S. Food and Drug Administration's review of
its new drug application for its inhaled-insulin product for diabetics will
require four additional weeks.
The biopharmaceutical company, which has no products on the market currently
, had been expecting FDA approval of Afrezza by Wednesday.
MannKind has been hoping to succeed where larger drug makers have failed. In
the mid-2000s, several companies were seeking to bring an inhaled
formulation of insulin to market as an alternative to injections.
The FDA initially had sought more information from MannKind in March about
how the available data support the clinical utility of Afrezza in the
marketplace, though the company at the time still planned a 2011 launch of
the product. The FDA accepted its resubmission in July.
The company also was dealt a setback in November when a former senior
manager accused the drug developer of unlawful practices in its conduct of
clinical trials, an accusation the company denies.
Shares closed Monday at $7.97 and were inactive premarket. The stock is
still down 9% this year, though it has recovered some of its losses since
the FDA's action in March.
-By Tess Stynes, Dow Jones Newswires; 212-416-2481; T*********[email protected]
(END) Dow Jones Newswires
12-28-10 0713ET
Copyright (c) 2010 Dow Jones & Company, Inc. |
D******9
发帖数: 2665 | |
C*******i
发帖数: 2131 | 4 MNDK 的call put option狂降！WTF |
b*****h
发帖数: 783 | 5 1月份用来赌fda结果的全被干掉。。
【在 C*******i 的大作中提到】
: MNDK 的call put option狂降！WTF
|
C*******i
发帖数: 2131 | 6 太黑了
【在 b*****h 的大作中提到】
: 1月份用来赌fda结果的全被干掉。。
|
S*******k
发帖数: 106 | 7 哈哈，俺卖的一月份9块的straddle赚发了！
【在 b*****h 的大作中提到】
: 1月份用来赌fda结果的全被干掉。。
|
f**********g
发帖数: 2252 | 8 CEO好像很看好，买了很多。
http://www.marketwatch.com/story/mannkind-ceo-bets-big-on-diabe
Mann, Alfred E
Purchase
1/11/2011
-0.04% 700.0K
$6.1M $8.71 - $8.71 50,848,400
Purchase
12/29/2010
-0.04% 700.0K
$5.8M $8.22 - $8.22 50,148,400
Purchase
12/15/2010
-0.04% 700.0K
$5.9M $8.46 - $8.46 49,448,400
Purchase
12/14/2010
-0.04% 700.0K
$5.9M $8.46 - $8.46 49,448,400
Purchase
10/20/2010
-0.04% 700.0K
$5.0M $7.15 - $7.15 48,748,400
【在 b*****h 的大作中提到】
: need about more 4 weeks.
|
b*****h
发帖数: 783 | 9 CEO Mann 一直很挺mnkd，不过这些transaction是以前就签好的协议，buy match
Seaside 88的短期投资。而且这些股票是直接用mnkd欠ceo的钱来抵的。
再一个星期就出最后结果了。呵呵，准备100股支持Mann 执着的biotech开发精神。
【在 f**********g 的大作中提到】
: CEO好像很看好，买了很多。
: http://www.marketwatch.com/story/mannkind-ceo-bets-big-on-diabe
: Mann, Alfred E
: Purchase
: 1/11/2011
: -0.04% 700.0K
: $6.1M $8.71 - $8.71 50,848,400
:
: Purchase
: 12/29/2010
|
b*****h
发帖数: 783 | 10 need about more 4 weeks. |
|
|
f**********g
发帖数: 2252 | 11 MannKind Says FDA Review Of Afrezza To Take Four More Weeks
0 minutes ago - Dow Jones News
Related Companies
Symbol Last %Chg
MNKD 7.97 0.00%
As of 4:00 PM ET 12/27/10
DOW JONES NEWSWIRES
MannKind Corp. (MNKD) said the U.S. Food and Drug Administration's review of
its new drug application for its inhaled-insulin product for diabetics will
require four additional weeks.
The biopharmaceutical company, which has no products on the market currently
, had been expecting FDA approval of Afrezza by Wednesday.
MannKind has been hoping to succeed where larger drug makers have failed. In
the mid-2000s, several companies were seeking to bring an inhaled
formulation of insulin to market as an alternative to injections.
The FDA initially had sought more information from MannKind in March about
how the available data support the clinical utility of Afrezza in the
marketplace, though the company at the time still planned a 2011 launch of
the product. The FDA accepted its resubmission in July.
The company also was dealt a setback in November when a former senior
manager accused the drug developer of unlawful practices in its conduct of
clinical trials, an accusation the company denies.
Shares closed Monday at $7.97 and were inactive premarket. The stock is
still down 9% this year, though it has recovered some of its losses since
the FDA's action in March.
-By Tess Stynes, Dow Jones Newswires; 212-416-2481; T*********[email protected]
(END) Dow Jones Newswires
12-28-10 0713ET
Copyright (c) 2010 Dow Jones & Company, Inc. |
D******9
发帖数: 2665 | |
C*******i
发帖数: 2131 | 13 MNDK 的call put option狂降！WTF |
b*****h
发帖数: 783 | 14 1月份用来赌fda结果的全被干掉。。
【在 C*******i 的大作中提到】
: MNDK 的call put option狂降！WTF
|
C*******i
发帖数: 2131 | 15 太黑了
【在 b*****h 的大作中提到】
: 1月份用来赌fda结果的全被干掉。。
|
S*******k
发帖数: 106 | 16 哈哈，俺卖的一月份9块的straddle赚发了！
【在 b*****h 的大作中提到】
: 1月份用来赌fda结果的全被干掉。。
|
f**********g
发帖数: 2252 | 17 CEO好像很看好，买了很多。
http://www.marketwatch.com/story/mannkind-ceo-bets-big-on-diabe
Mann, Alfred E
Purchase
1/11/2011
-0.04% 700.0K
$6.1M $8.71 - $8.71 50,848,400
Purchase
12/29/2010
-0.04% 700.0K
$5.8M $8.22 - $8.22 50,148,400
Purchase
12/15/2010
-0.04% 700.0K
$5.9M $8.46 - $8.46 49,448,400
Purchase
12/14/2010
-0.04% 700.0K
$5.9M $8.46 - $8.46 49,448,400
Purchase
10/20/2010
-0.04% 700.0K
$5.0M $7.15 - $7.15 48,748,400
【在 b*****h 的大作中提到】
: need about more 4 weeks.
|
b*****h
发帖数: 783 | 18 CEO Mann 一直很挺mnkd，不过这些transaction是以前就签好的协议，buy match
Seaside 88的短期投资。而且这些股票是直接用mnkd欠ceo的钱来抵的。
再一个星期就出最后结果了。呵呵，准备100股支持Mann 执着的biotech开发精神。
【在 f**********g 的大作中提到】
: CEO好像很看好，买了很多。
: http://www.marketwatch.com/story/mannkind-ceo-bets-big-on-diabe
: Mann, Alfred E
: Purchase
: 1/11/2011
: -0.04% 700.0K
: $6.1M $8.71 - $8.71 50,848,400
:
: Purchase
: 12/29/2010
|
